Added to YB: 2024-06-19
Pitch date: 2024-06-18
HUMA [bullish]
Humacyte, Inc.
-92.29%
current return
Author Info
No bio for this author
Company Info
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
Market Cap
$165.6M
Pitch Price
$5.71
Price Target
7.50 (+1605%)
Dividend
N/A
EV/EBITDA
-1.48
P/E
-1.20
EV/Sales
71.92
Sector
Biotechnology
Category
growth
Humacyte Valuation Seen as Attractive by TD Cowen, Price Target Raised
HUMA: TD Cowen maintains Buy, raises PT to $7.50 on innovative regenerative medicine pipeline targeting large market. Proprietary tech could disrupt traditional treatments. Undervalued at current price given future revenue potential from pending approvals & commercialization.
Read full article (1 min)